Gennova Biopharmaceuticals Limited, a active public limited company, was established on 19 June 2001 in Pune City, Maharashtra, India. Engaging in biotechnology within the manufacturing sector, it holds CIN: U24231PN2001PLC016253. Registered under ROC Roc Pune. it is unlisted. It has an authorized capital of ₹65.00 Cr and a paid-up capital of ₹5.51 Cr.
Formerly known as Emcure Dragon Biotech Limited. It upholds a compliant status. Employing 705 professional, Its leadership includes Shailesh Kripalu Ayyangar (Director), Sanjay Singh (Ceo), Vikas Madan Thapar (Additional Director). Past directors included Shailesh Kripalu Ayyangar, Girish Laxmikant Telang, Sachin Kaushik. It holds ₹212.90 Cr open charges and ₹133.73 Cr settled loans. Its latest AGM occurred on 28 August 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. P-1 & P-2,, It-Bt Park, Phase - Ii, M.I.D.C., Pune City, Maharashtra, 411057.
U24231PN2001PLC016253
016253
19 June 2001
₹65.00 Cr
₹5.51 Cr
Roc Pune
Unlisted
Active
Explore comprehensive insights into Gennova Biopharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shailesh Kripalu Ayyangar | Director | 26 Jul 2021 | Current |
| Sanjay Singh | Ceo | 27 Oct 2020 | Current |
| Vikas Madan Thapar | Additional Director | 07 Nov 2024 | Current |
| Kavita Singh | Director | 24 Jan 2023 | Current |
| Samit Satish Mehta | Whole-Time Director | 09 Sep 2011 | Current |
| Sunil Rajanikant Mehta | Director | 19 Jun 2001 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Jul 2021 | Past |
| Pramod Abcsdd | Director | 12 Sep 2018 | Past |
| Pramod Abcsdd | Cfo(Kmp) | - | Past |
| Pramod Abcsdd | Director | 27 Jul 2021 | Past |
| Pramod Abcsdd | Director | 18 May 2009 | Past |
| Pramod Abcsdd | Additional Director | 19 Aug 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Gennova Biopharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.75% increase. The company also saw a substantial improvement in profitability, with a 83.26% increase in profit. The company's net worth Soared by an impressive increase of 16.5%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Gennova Biopharmaceuticals had a promoter holding of 87.95% and a public holding of 12.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,129,000,000.00
₹1,337,324,709.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Oct 2022 | Citi Bank N.A. | ₹50.00 Cr | Open |
| 20 May 2022 | Axis Bank Limited | ₹55.00 Cr | Open |
| 02 Sep 2021 | Others | ₹107.00 Cr | Open |
| 30 Jun 2021 | Axis Bank Limited | ₹9.00 M | Open |
| 25 Jun 2021 | Others | ₹22.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Gennova Biopharmaceuticals has a workforce of 705 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Gennova Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gennova Biopharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Gennova Biopharmaceuticals Limited last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records. was completed.
Progress on Gennova Biopharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Pune. was documented.
Progress on Vikas Madan Thapar was appointed as a Additional Director was appointed as a Additional Director on 07 Nov 2024 & has been associated with this company since 1 year 23 days . was documented.
A charge with Others of Rs. 107.00 Cr registered on 02 Sep 2021 with Charge ID 100483894 was modified on 07 Mar 2024. was recorded as a recent event.
A charge registered on 11 Jan 2017 via Charge ID 100126176 with Others was fully satisfied on 28 Feb 2024. was recorded as a recent event.
A charge registered on 30 Jun 2004 via Charge ID 90086867 with The Bank Of Maharashtra Limited was fully satisfied on 28 Feb 2024. was recorded as a recent event.
The mRNA-based vaccine was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC)..
The CIN of Gennova Biopharmaceuticals Limited is U24231PN2001PLC016253.
Gennova Biopharmaceuticals Limited is headquartered at Plot No. P-1 & P-2,, It-Bt Park, Phase - Ii, M.I.D.C., Pune City, Maharashtra, 411057.
Gennova Biopharmaceuticals Limited was incorporated on 19 June 2001.
The current directors of Gennova Biopharmaceuticals Limited are
The primary industry of Gennova Biopharmaceuticals Limited is Manufacturing.
Gennova Biopharmaceuticals Limited is unlisted.
The authorized capital of Gennova Biopharmaceuticals Limited is ₹65.00 Cr, and the paid-up capital is ₹5.51 Cr.
The compliance status of Gennova Biopharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX